Diabetes Clinical Trials in San Francisco

Showing 141-160 of 255 trials

Study of Antithymocyte Globulin for Treatment of New-onset T1DM

NCT00515099

Antithymocyte globulin (e.g., Thymoglobulin®) is an antibody preparation that is commonly used to treat and prevent organ transplant rejection. The START trial aims to determine whether antithymocyte globulin (ATG) treatment can halt the progression of newly diagnosed type 1 diabetes when given within 12 weeks of disease diagnosis.

New-onset Type 1 Diabetes Mellitus

National Institute of Allergy and Infectious Diseases (NIAID)58 participantsStarted Aug 2007

Los Angeles, California, United States • Oakland, California, United States • San Diego, California, United States +6 more locations

COMPLETEDPHASE213 miles

Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive

NCT00495469

This is a dose-ranging study to evaluate the efficacy, safety and tolerability of a range of doses of GSK189075 (an SGLT2 inhibitor) compared to placebo, administered over 12 weeks in treatment-naive subjects with type 2 diabetes mellitus

Diabetes Mellitus, Type 2

GlaxoSmithKline250 participantsStarted Aug 2007

Mesa, Arizona, United States • Artesia, California, United States • Buena Park, California, United States +154 more locations

Study of Antithymocyte Globulin for Treatment of New-onset T1DM

Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive

Diabetes Trials in Other Cities

A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin

Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus

The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)

Injection Site Study In Patients With Type 2 Diabetes Mellitus (T2DM) And Healthy Volunteers

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes

Assessment of an Automatic Closed-loop Insulin Delivery System

Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)

Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes

Study In People With Type 2 Diabetes

Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen

Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes

Thiazolidinedione Intervention With Vitamin D Evaluation

A Study of LY2405319 in Participants With Type 2 Diabetes

Other Conditions in San Francisco